Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

American Neurological Association Annual 2012 Annual Meeting
FDA approves Genzyme’s AUBAGIO® (teriflunomide), a once-daily, oral treatment for relapsing multiple sclerosis
Treatment Options to Reduce Disease Activity After Natalizumab: Paradoxical Effects of Corticosteroids.
The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada.
Primary Progressive MS evolving from Radiologically Isolated Syndrome.
Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
Interferon beta 1a anaphylaxis, a case report. Standardization of non-irritating concentration for allergy skin.
Clinical Epigenetics International Meeting
Effects of a 4-month Ananda Yoga Program on Physical and Mental Health Outcomes for Persons With Multiple Sclerosis.
Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS).
Safety and tolerability of daclizumab HYP treatment in relapsing-remitting multiple sclerosis: results of the DECIDE study
Polymorphism in Leptin and Leptin Receptor Genes May Modify Leptin Levels and Represent Risk Factors for Multiple Sclerosis.
Quantifying brain volumes for Multiple Sclerosis patients follow-up in clinical practice - comparison of 1.5 and 3 Tesla magnetic resonance imaging.
Is No Evidence of Disease Activity a Realistic Goal for Patients With Multiple Sclerosis?
Dimethyl fumarate (BG-12, Tecfidera) approved for use by the NHS in Scotland
Mechanism of action for leflunomide in rheumatoid arthritis.
Results from Two Phase III Studies Added to U.S. Label of Genzyme’s Aubagio
WT1 and interferon-β-vitamin D association in MS: a longitudinal study.
Ampyra (Fampyra)
Geography in multiple sclerosis.
How integrated are neurology and palliative care services? Results of a multicentre mapping exercise.
FDA product review for daclizumab
CHMP determines dimethyl fumarate in TECFIDERA® to be a new active substance in the European Union
Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy.
Assessment of cancer risk with β-interferon treatment for multiple sclerosis.

Pages